Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RARE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.68B
- Forward P/E
- 11.50
- EPS (TTM)
- -$5.17
- Dividend yield
- None
- 52-week range
- 12.73 – 39.89
- Day range
- 16.43 – 17.35
- Volume / Avg
- 3.01M / 4.69M
- Beta
- —
- Shares outstanding
- 101.92M
52-week range
RARE stock today
On Nov 20, RARE ended the session at $16.48, shedding $0.74 (4.30%), versus the S&P 500's 3.70% decline. At this level, RARE sits near the bottom of its 52-week range of $12.73 to $39.89: 58.7% below the high, set on Dec 8, 2025 and 29.5% above the low. RARE is down 28.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.9%.
Ultragenyx Pharmaceutical has posted a net loss over the last twelve months (EPS of -$5.17), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ultragenyx Pharmaceutical
Company profileUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Emil D. Kakkis M.D., Ph.D.
- Headquarters
- Novato, CA
- Employees
- 1,371
- IPO year
- 2014
- Website
- ultragenyx.com
Financial highlights
Full financialsIn fiscal 2025, Ultragenyx Pharmaceutical generated $673.0 million in revenue, up 20.2% from fiscal 2024, its 9th consecutive year of revenue growth. Ultragenyx Pharmaceutical reported a net loss of $575.0 million, compared with a loss of $569.0 million a year earlier. Operating margin was -79.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $673.00M | $560.00M | $434.00M | $363.33M | $351.41M |
| Growth | +20.18% | +29.03% | +19.45% | +3.39% | +29.66% |
| Net income | $-575.00M | $-569.00M | $-607.00M | $-707.42M | $-454.02M |
| EPS (diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
Analyst forecast
ForecastConsensus (21 analysts)
buy
Avg. price target
$24.80+50.49%
- Strong buy 2
- Buy 8
- Hold 11
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-1.81 vs $-1.15
- Surprise
- -57.39%
RARE news
All RARE news- Ultragenyx to Participate at Investor Conferences in LondonGlobeNewswire
- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots SplitNasdaqABT, AGIO, BEAT, BIOA
- Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)GlobeNewswire
- Ultragenyx Q3 Loss Narrows; Reaffirms 2027 Profit OutlookNasdaq
- Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027GlobeNewswire
- GSK (GSK) Q3 Earnings and Revenues Beat EstimatesNasdaqGSK, RARE
- Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseNasdaqRARE, JAZZ
- Stocks Finish Mostly Higher on Earnings OptimismNasdaqALK, RARE, TRI, AMGN
Ultragenyx Pharmaceutical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BRVEBraveheart Bio Inc. | 20.39 | +5.81% | $1.67B | vs RARE |
| AGIOAgios Pharmaceuticals Inc. | 27.60 | -4.03% | $1.65B | vs RARE |
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs RARE |
| SDGRSchrodinger Inc. | 22.93 | -12.95% | $1.72B | vs RARE |
| ZBIOZenas BioPharma Inc. | 23.85 | -4.75% | $1.62B | vs RARE |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs RARE |
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs RARE |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs RARE |
Indexes, lists and sector
Ultragenyx Pharmaceutical stock FAQ
What is Ultragenyx Pharmaceutical's stock price today?
RARE last traded at $16.48 as of Nov 20, 4:00 PM EST, down 4.30% on the day. Prices are delayed at least 15 minutes.
Who is Ultragenyx Pharmaceutical's CEO?
Dr. Emil D. Kakkis M.D., Ph.D. is the chief executive officer of Ultragenyx Pharmaceutical Inc., which has about 1,371 employees.
What is the RARE 52-week high?
The 52-week high for RARE is $39.89 and the 52-week low is $12.73. The stock is currently 58.7% below its high.